HB0034

DRUG5 trials

Sponsors

Shanghai Huaota Biopharmaceutical Co., Ltd.

Conditions

Generalized Pustular PsoriasisGeneralized Pustular Psoriasis (GPP)Healthy

Phase 1

A Study to Evaluate HB0034 in Healthy Adult Participants

CompletedNCT05064345

Shanghai Huaota Biopharmaceutical Co., Ltd.Healthy

Start: 2021-12-03End: 2022-09-01Updated: 2022-09-14

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

CompletedNCT05512598

Shanghai Huaota Biopharmaceutical Co., Ltd.Generalized Pustular Psoriasis

Start: 2022-11-06End: 2024-01-10Updated: 2024-01-23

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

RecruitingNCT06716151

Shanghai Huaota Biopharmaceutical Co., Ltd.Healthy

Start: 2024-12-06End: 2025-11-20Target: 60Updated: 2025-01-20

Phase 2

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

RecruitingNCT06231381

Shanghai Huaota Biopharmaceutical Co., Ltd.Generalized Pustular Psoriasis (GPP)

Start: 2024-02-29End: 2025-11-30Target: 33Updated: 2025-03-19

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

RecruitingNCT06477536

Shanghai Huaota Biopharmaceutical Co., Ltd.Generalized Pustular Psoriasis

Start: 2024-09-02End: 2026-06-30Target: 33Updated: 2025-02-14